EyeGate Pharma Initiates Phase III Study of EGP-437 in Patients With Anterior ... MarketWatch (press release) The randomized double-masked positive-controlled non-inferiority study will enroll up to 200 subjects at more than 20 US sites in order to assess the effectiveness of EGP-437 in comparison to topically applied prednisolone acetate eye drops. ... |
